The serine proteases urokinase-type plasminogen activator (uPA) and plasmin, in concert with other proteolytic enzymes (e. g. matrix metalloproteases, cysteine proteases), are involved in tumor-associated processes such as cell invasion and regulation of cell/cell and cell/matrix contacts Schmitt et al., 2000; Andreasen et al., 2000) . (pro-)uPA binds to a specific, high-affinity cell surface receptor, uPAR (CD87), which is composed of three structurally homologous, independently folded domains (Dear and Medcalf, 1998) . In addition, there are also cellular binding sites for plasmin(ogen) (Félez, 1998) . In consequence, binding of (pro-) uPA to cell membrane-anchored uPAR significantly increases plasmin generation due to a distinct increase of reciprocal activation of pro-uPA and plasminogen (Ellis et al., 1991) . Plasmin not only degrades a variety of components of the extracellular matrix (e. g. fibrin and laminin), but also activates certain matrix metalloproteases (in addition to pro-uPA) which break down additional structural proteins of the extracellular matrix such as various collagens. Thus, cell surface-triggered plasminogen activation plays a fundamental role in tissue remodeling, which is a prerequisite for tumor cell invasion and metastasis Schmitt et al., 2000; Andreasen et al., 2000) .
Introduction
The serine proteases urokinase-type plasminogen activator (uPA) and plasmin, in concert with other proteolytic enzymes (e. g. matrix metalloproteases, cysteine proteases), are involved in tumor-associated processes such as cell invasion and regulation of cell/cell and cell/matrix contacts Schmitt et al., 2000; Andreasen et al., 2000) . (pro-)uPA binds to a specific, high-affinity cell surface receptor, uPAR (CD87), which is composed of three structurally homologous, independently folded domains (Dear and Medcalf, 1998) . In addition, there are also cellular binding sites for plasmin(ogen) (Félez, 1998) . In consequence, binding of (pro-) uPA to cell membrane-anchored uPAR significantly increases plasmin generation due to a distinct increase of reciprocal activation of pro-uPA and plasminogen (Ellis et al., 1991) . Plasmin not only degrades a variety of components of the extracellular matrix (e. g. fibrin and laminin), but also activates certain matrix metalloproteases (in addition to pro-uPA) which break down additional structural proteins of the extracellular matrix such as various collagens. Thus, cell surface-triggered plasminogen activation plays a fundamental role in tissue remodeling, which is a prerequisite for tumor cell invasion and metastasis Schmitt et al., 2000; Andreasen et al., 2000) .
The interaction of pro-uPA or its activated form high molecular weight (HMW-)uPA with uPAR has been characterised in detail. Although the N-terminal domain I of uPAR contains major determinants for uPA-binding, high affinity interaction with uPA is dependent on the multidomain structure of the receptor, indicating that all three protein domains are involved in the formation of a composite ligand binding site (Ploug, 1998; Gårdsvoll et al., 1999; Bdeir et al., 2000) . In contrast, uPA binds to uPAR via a defined continuous peptide sequence Biol. Chem., Vol. 382, pp. 1197 -1205 ) within the N-terminal region of uPA. Originally, the uPAR-binding epitope of uPA was identified by applying a linear peptide spanning amino acids 12 -32 of uPA (in which, for technical reasons, Cys19 was substituted by Ala) in competition experiments (Appella et al., 1987) . This peptide was found to inhibit binding of the amino-terminal fragment (ATF) of uPA (which binds to uPAR with the same affinity as uPA but lacks the uPA protease domain) to cell surface uPAR. Later, several linear peptides spanning uPA [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] were synthesised in which the naturally occurring amino acids were individually replaced by alanine (Ala scan) in order to identify the amino acids critical for binding to uPAR (Magdolen et al., 1996) . The exchange of Cys19, Lys23, Tyr24, Phe25, Ile28, Trp30, and Cys31, respectively, by Ala resulted in peptides with strongly impaired uPAR-binding capacities, whereas replacement of the other amino acids had no or little effect on uPAR binding. Finally, the minimal uPAR-binding region of uPA was located to uPA 19-31 using synthetic peptides which were successively shortened from the amino-and/or carboxy-terminus starting with uPA 10-32 (Bürgle et al., 1997) .
The region between amino acids Thr18 and Asn32 of uPA consists of a flexible, seven-residue Ω-loop (Asn22 to Ile28) which by means of a double stranded, antiparallel ß-sheet (between Thr18 to Ser21 and His29 to Asn32) is forced into a ring-like structure (Hansen et al., 1994a, b; Magdolen et al., 1996; Schmitt et al., 2000) . In uPA, Cys19 and Cys31, although in close proximity, form disulfide bonds with distinct cysteines (Cys11/Cys19 and Cys13/Cys31, respectively; Hansen et al., 1994a, b) . The short distance between Cys19 and Cys31 in the native molecule may explain why peptide cyclo 19, 31 uPA 19-31 with its 'illegitime' disulfide bond retains or displays an even increased uPAR-binding activity (Bürgle et al., 1997) . Recently, we successfully generated double-headed inhibitors directed at different tumor-associated proteolytic systems by exchanging a disulfide-linked loop in cystatin, which is non-essential for cysteine protease inhibition, with uPA [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . The results obtained indicate that cystatins with a uPAR-binding site are efficient inhibitors of cysteine proteases and uPA/uPAR-interaction at the same time (Muehlenweg et al., 2000) .
Other types of peptide antagonists of uPA/uPAR-interaction, which show no obvious similarity to uPA [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] , have been identified by a bacteriophage peptide display approach (Goodson et al., 1994) . All of the reactive peptides (with the clone 20 peptide being most active) harbor relatively short common motifs, such as LWXXY and FXXYLW, which may represent a variation of the motif 24 YFXXIXW 30 within the uPA molecule (only the critical hydrophobic amino acids for uPAR-binding are depicted) (Magdolen et al., 1996; Bürgle et al., 1997) . Recently, a non-competitive, allosteric antagonist of prouPA/uPAR-interaction (Å6-peptide) derived from a non-receptor binding region of uPA ) has been identified (Guo et al., 2000) . As demonstrated in various experimental in vivo model systems for competitive inhibitors of uPA/uPAR-interaction (Crowley et al., 1993; Min et al., 1996; Kobayashi et al., 1998; Li et al., 1998; Tressler et al., 1999; Krüger et al., 2000; Lutz et al., 2001) , administration of this non-competitive antagonist to tumor-bearing animals did also inhibited tumor growth and metastasis.
In the present study, the synthetic peptide cyclo 19, 31 uPA 19-31 was used as a lead structure to identify more potent small molecule inhibitors of uPA/uPAR-interaction. Initially, we substituted each of the 13 L-amino acids of peptide uPA [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] individually by the corresponding D-amino acid. Subsequently, cyclic counterparts of those D-amino acid-containing peptides still displaying distinct uPAR-binding capacities were generated. In addition, we also synthesised the retro-inverso variant of cyclo 19, 31 uPA [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] 
Results and Discussion

Stereochemical Modifications of uPA 19-31
Substitution of L-amino acids by corresponding D-amino acids in peptide analoga may yield additional information with respect to the stereochemical basis for the generation of specific secondary structures and their input on the interaction of the peptide ligand with its receptor. Furthermore, since most proteases are enantio-specific, and therefore do not cleave peptide bonds which are built up by D-/L-or L-/D-amino acids, the use of D-amino acids may also significantly improve the in vivo stability of such peptide analoga. D-amino acids in peptide ligands may also induce so-called ß-turns and, therefore, increase the rigidity of structural motifs which are important for the binding conformation.
We replaced each of the 13 L-amino acids of the linear peptide uPA [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] individually by the corresponding D-amino acid. After purification by HPLC, the ability of these peptides to inhibit binding of fluorescently labeled uPA to uPAR-expressing human U937 cells was tested by flow cytofluorometry. The substitution of some L-amino acids by corresponding D-amino acids in uPA [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Lys23, Tyr24, Phe25, Ser26, Ile28, and Cys31) significantly reduced the binding capacities of these peptide variants as compared to the parental peptide uPA [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] (Table 1) . This points to the fact that the stereochemical orientation of these amino acids may be important for binding or that certain D-amino acids induce a structural change in the uPA 19-31 -variant, thereby leading to a reduced interaction with uPAR. Interestingly, these (Table 1) .
Cyclic D-Amino Acid-Containing Variants of uPA 19-31
Cyclic counterparts of the linear uPA 19-31 -derived peptides that display an inhibitory activity towards uPA/uPARinteraction in the FACS analyses were generated, HPLC- -uPA 19-31 about 700 nM. The IC 50 value of both unlabelled human uPA and ATF was 5 -10 nM. Thus, the binding affinity of the D-Cys19-modified uPA-peptide is only 20-to 40-fold lower than that of the naturally occurring uPAR-ligands uPA and ATF.
Other Cyclic uPA-Derived Peptide Variants
In addition to the peptides with single D-amino acid substitutions, we generated a cyclic peptide in which all L-amino acids were substituted by their corresponding D-enantiomers and in which all of the peptide bonds were inverted. This approach resulted in the so-called retro-inverso, protease-insensitive peptide of cyclo 19, (Figure 2 ).
As initially proposed by Prelog and Gerlach (1964) and Shemyakin et al. (1969) , the complete inversion of all chirality centers, together with the inversion of the amino acid sequence should lead to a similar topochemical orientation of the side chains than the parent peptide, provided the topology of the intramolecular hydrogen bonds is neglected. Indeed, several groups have observed that retroenantiomeric peptides may display comparable biological activities as the parent peptides (Chorev and Goodman, 1993) . In line with this, the structural evaluation of a cyclic Fcε RI α-chain-derived peptide and its retro-inverso motif by NMR showed similarity of the surface topology of both compounds (McDonnell et al., 1997) . However, as demonstrated by Wermuth et al. (1997) , the topology of the α v β 3 integrin inhibitor cyclo (-RGDfV-) and its retro-inverso peptide can differ, resulting in different activity profiles of the derivative or even complete loss of biological activity.
The retro-inverso peptide of uPA [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] did not show any uPAR-binding activity (Figure 1 ). This may due to the fact [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] --
The uPAR-binding capacities of linear and cyclic uPA-derived variants were tested by flow cytofluorometry. For this, PMAstimulated human U937 cells (2.5 × 10 5 cells per 250 µl) were coincubated with 16 ng FITC-pro-uPA and varying amounts of the uPA-peptides, and the cell-associated fluorescence was determined. Key: ++++, efficient competition of FITC-pro-uPA binding with < 1 µg peptide; +++, efficient competition with < 2.5 µg; ++, about 50% competition with 2.5 µg; (+/-), weak inhibition of FITC-pro-uPA binding with ≥ 10 µg peptide; -, no inhibition; n.t., not tested; Hph, homophenyl-alanine. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] (for the primary structure see Figure 2 ) exerts no effect. The result is representative of three independently performed experiments.
that retro-D-peptides harbor exchanged N-and C-termini ( Figure 2 ) and that these terminal groups in the peptide cyclo 19, are important for the interaction with uPAR. Alternatively, the amide bonds in the backbone of the peptide (which are reversed in the retro-inverso peptide) may be necessary for the binding of the uPA-derived peptide to uPAR. One also has to take into account that the hydrogen bond pattern in retro-inverso peptides is different as compared to the parental peptides.
To further elucidate the importance of Cys19 and Cys31 in cyclic uPA-peptides for binding to uPAR, we generated two other peptide variants: (i) cyclo 20, 30 uPA [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] was generated by the formation of a peptide bond of the terminal -NH 2 group of Val20 and the terminal -COOH group of Trp30; (ii) cyclo . This thioether analogue of the cystine is found in a variety of natural products, mainly in 'lantibiotics' such as nisin, subtilin, and cinnamycin (Jung, 1991; Sahl et al., 1995) . The biosynthesis of the lanthionine peptides occurs ribosomally by posttranslational stereoselective Michael-like addition of cysteine to dehydroalanine and always results in a D-configuration at the generated asymmetric center (Sahl et al., 1995) . Due to the increased interest in lantibiotics in pharmaceutical research, serveral routes to synthesise the mentioned thioether moiety were examined. Among these are the Michael-type addition to dehydroalanines (Miller, 1980; Probert et al., 1996) , nucleophilic ring-opening of serine-ß-lactones (Shao et al., 1995; Arnold et al., 1998) , sulfur extrusions of protected peptides (Wakamiya et al., 1983) , in situ alkylations of immobilised peptidyl cysteine residues (Mayer et al., 1998) , and asymmetric alkylations of cysteines with ß-iodo-alanine derivatives (Dugave and Ménez, 1997) . In our hand, the last mentioned method worked best regarding practical and chemical considerations.
In native human uPA, the distance between the Cα-atoms of Cys19 and Cys31 (which are not connected by a disulfide bond) is 6.1 Å (Hansen et al., 1994a, b) -uPA 19-31 significantly lower -inhibitory activity with respect to interference with the uPA/uPAR-interaction (Table 1) . This indicates that the cystine-bridge in the lead uPA-peptide structure could be modified by peptido-mimetica to some extent. In previous studies (Bürgle et al., 1997) Table 1 ) had no effect. As controls, the amino-terminal fragment of uPA (ATF), which also blocks binding of endogenously produced uPA to the cell surface, or a monoclonal antibody directed against human uPA, which inhibits the proteolytic activity of uPA, was employed. In both cases, a significant reduction of uPA-mediated plasminogen activation and, in consequence, fibrin degradation was observed ( Figure 4) .
Conclusions
Due to its important role in tumor-associated processes the urokinase-type plasminogen activation system emerged as an attractive target for anti-invasive and antimetastatic therapy. Over the past years, a variety of substances known to interfere with the expression or reactiv- [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] ) has no effect. The result is representative of three independently performed experiments. . uPA-producing ovarian cancer cells (OV-MZ-6) were seeded on fibrin gels in the presence of plasminogen (2 µg/ml medium) together with increasing amounts of synthetic peptides (2.5, 10 and 20 µM, respectively). As controls, either ATF (2 µg/ml medium) or mAb # 394 directed against human uPA (10 µg/ml medium) were added instead of the synthetic peptides. After 4 h, cell culture supernatants were analysed for the presence of D-dimer as the result of fibrin degradation by plasmin. Mohan et al., 1999) , protease inhibitors (Towle et al., 1993; Sperl et al., 2000) , recombinant soluble uPAR Lutz et al., 2001) , or uPA-derived antagonists of uPA/uPAR-interaction. In the latter case, mostly large therapeutic molecules were generated and tested in vivo. For example, it was demonstrated that a uPA 1-137 /IgG-chimera suppressed the metastatic capacity of human PC3 prostate carcinoma cells in nude mice (Crowley et al., 1993) . Similarly, reduction of growth of primary human breast carcinoma in immunodeficient mice was observed by administration of a fusion protein consisting of human or murine uPA fused to the Fc portion of human IgG (Tressler et al., 1999) . A bifunctional inhibitor, consisting of uPA fused to domain II of the urinary trypsin inhibitor (UTI), suppressed experimental tumor invasion and metastasis by blocking uPA/uPAR-interaction via the amino-terminal fragment of uPA within this chimeric molecule and by inhibition of plasmin activity via UTI (Kobayashi et al., 1998) . The application of large molecules to treat cancer patients appears rather difficult and depends on sophisticated, e. g. viral, delivery systems. Consequently, our aim was to develop synthetic, small peptide inhibitors derived from the continuous uPAR-binding sequence of uPA (Magdolen et al., 1996; Bürgle et al., 1997) . Using the cyclic disulfide-bridged form of the minimal uPAR-binding region as lead structure (cyclo -uPA 19-31 inhibits binding of uPA to uPAR on human tumor cells with more than 3-fold higher efficiency compared to the lead structure and at least with 10-fold higher efficiency compared to a high affinity uPAR ligand (clone 20 peptide) derived from bacteriophage display (Goodson et al., 1994; Bürgle et al., 1997) . Furthermore, cyclo 19, 31 [D-Cys 19 ]-uPA 19-31 efficiently displaces uPAR-bound uPA from the cell surface of human cells and inhibits uPA-mediated, cell-associated plasminogen activation and fibrin degradation. We are currently synthesising a series of cyclo 19, 31 [D-Cys 19 ]-uPA 19-31 -variants, in which particular amino acids are substituted by amino acids not occuring in natural proteins (e. g. substitution of lysine by ornithine or norleucine; tryptophan by 1-naphthyl-or 2-naphthyl-alanine, etc.). This strategy may lead to high affinity uPA-antagonists with increased biological availability due to higher resistance against proteolytic degradation. Recently, a synthetic non-competitive peptidic antagonist of the pro-uPA/uPAR-interaction, the Å6-peptide, has been successfully tested in vivo. The administration of Å6 -in a rather high concentration of 75 mg per kg per day -resulted in a significant inhibition of tumor growth and also suppressed the development of lymph node metastases in both syngeneic (rat breast cancer) and xenogeneic (human breast cancer in nude mice) tumor model systems (Guo et al., 2000) . Thus, high affinity competitive antagonists of uPA/uPAR-interaction, such as cyclo 19, 31 [D-Cys 19 ]-uPA 19 -31 or variants thereof, may constitute potent therapeutic agents for inhibition of tumor growth and metastasis.
Materials and Methods
Solid-Phase Peptide Synthesis
Linear peptides were synthesised on a trityl polystyrene resin (PepChem, Tübingen, Germany) using an Applied Biosystems model 431A peptide synthesiser or a multiple peptide synthesiser, model SyRo II (MultiSynTech, Witten, Germany) . Applying an orthogonal Fmoc-strategy (Carpino and Han, 1972; Fields and Noble, 1990) , the amino acid side chains were protected with trityl-(Asn, Cys, Gln, and His), tert-butyloxycarbonyl-(Lys and Trp), tert-butyl (Asp, Glu, Ser, Thr, and Tyr), and 2,2,5,5,7,8-pentamethylchroman-6-sulfonyl-or 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Arg) groups. Couplings were performed twice for 1 h each at room temperature (RT) in NMP using a 3-fold excess of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU)/1-hydroxybenzotriazole (HOBt)/Fmoc-amino acid with 2.8 equivalents of N,N-diisopropylethylamine (DIEA) in NMP. The Fmoc-group was removed by sequential treatment of the resins with an excess of 20% piperidine in DMF for 5 and 15 min, respectively. Cleavage of the peptides from the resins as well as removal of the side chain protecting groups, and work up was performed as follows (a and b, respectively):
(a) treatment with 82.5% trifluoroacetic acid (TFA)/5% phenol/2.5% ethanedithiol/5% thioanisol/5% H 2 O (0 ºC, 1 h; followed by RT, 1 h). In the case of 2,2,5,5,7,8-pentamethylchroman-6-sulfonyl protected Arg, peptides were treated for additional 12 h at RT. The crude peptides were precipitated in diethylether at -30 ºC, dissolved in methanol, precipitated as before, redissolved in tBuOH and then lyophilised. Tryptophancontaining peptides were treated additionally with 5% AcOH for 2 h prior to lyophilisation (White, 1992) . Peptides were purified by HPLC using a Beckman Instruments System Gold or a Pharmacia Biotech Series 900 with a reversed phase C-18 column (Nucleosil 100 5-C18) or a YMC-Pack ODS/A column with H 2 O and ACN plus 0.1% TFA as eluents applying an optimised gradient. Peptides cyclised via disulfide bridges were synthesised from the linear precursors through oxidation as described under (b).
(b) Treatment with 90% TFA/7% triisopropylsilane (TIPS)/3% H 2 O (RT, 3 × 15 min). The solution was evaporated, the resulting white solid powder suspended in H 2 O (0.1 -0.3 mg/ml of the crude peptide), cooled with ice and diluted with DMSO (end concentration: 20% v/v). After 10 -24 h the solvent was removed under reduced pressure, the resulting white solid powder dissolved in DMSO, diluted with an equal aliquot of H 2 O, filtered, and purified by HPLC as described above.
Backbone cyclisation of uPA 20-30 was performed as follows: the N-terminally deprotected peptidyl-resin was treated with 75% DCM/12.5% trifluoroethanol (TFE)/12.5% AcOH (RT, 2 h) and filtered. The resin was washed twice with DCM. The pooled solutions were evaporated in the presence of toluene and the resulting oil lyophilised from dioxane to yield a white powder. The linear peptide was dissolved in dry DCM/DMF (7:3 v/v, 0.4 mM). 1,3-diisopropylcarbodiimide (DIC), N-methylmorpholine (NMM), and 1-hydroxy-7-azabenzotriazole (HOAt) (1, 4, 2 equivalents, respectively) were added at 0 °C under vigorous stirring. The solution was kept unstirred at 4 °C for 24 h when the completion of the reaction was indicated by HPLC analysis. The solvents were evaporated, the resulting oil dissolved in DCM, washed with H 2 O, dried over Na 2 SO 4 and the solvent then removed under reduced pressure. After lyophilisation from dioxane, side-chain deprotection was achieved as described above (method b), followed by HPLC purification.
Synthesis of cyclo 19, 31 [Ala 19 -S-Ala 31 ]-uPA [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] : the lanthionine building block (R)-benzyl-N-triphenylmethylalanyl-(R)-methyl-N-benzyloxycarbonylalanylsulfide was prepared from N-benzyloxycarbonyl-L-cysteinemethylester and N-triphenylmethyl-3-iodo-L-alaninebenzyl-ester according to a procedure published by Dugave and Ménez (1997) . The suitable orthogonally protected (R)-benzyl-N-fluorenylmethyloxycarbonylalanyl-(R)-methyl-N-benzyloxycarbonyl-alanylsulfide was prepared by deprotection (1.2 eq. LiOH in H 2 O/dioxane at pH 8 -9, followed by treatment with 50% TFA/DCM) and reprotection with 1.1 eq. N-(9-fluorenylmethyloxycarbonyl)oxysuccinimide (Fmoc-ONSu)/ DIEA, followed by flash chromatography over silica gel with an optimised hexane/ethyl acetate gradient including AcOH concentrations ranging from 0 and 10%. This lanthionine derivative was coupled to H-Val-Ser(tBu)-Asn(Trt)-Lys(Boc)-Tyr(tBu)-TCP as described above, followed by Fmoc deprotection, coupling of Fmoc-Phe-Ser(tBu)-Asn(Trt)-Ile-His(Trt)-Trp(Boc)-OH with 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU)/HOAt/sym-collidine (1, 1, 10 eq., respectively) and Fmoc deprotection. The resulting peptide was cleaved from the resin, cyclised and side-chain deprotected as described for the cyclo 20,30 uPA [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . The resulting peptide cyclo 19, 31 [L-Ala19(Z)-S-L-Ala31(OBn)]-uPA 19-31 was purified by HPLC and completely deprotected by treatment with 80% TFA, 10% trifluoromethanesulfonic acid (TFMS), 5% TIPS and 5% m-cresole (RT, 30 min). Preparative HPLC followed by lyophilisation from tBuOH yielded the desired peptide as a white solid.
Mass spectrometric and amino acid analysis for characterisation and quantitation of the peptide concentration was performed as described previously (Bürgle et al., 1997) .
Flow Cytofluorometry
The capacity of synthetic peptides to inhibit uPA/uPAR-interaction was assessed by FACS analysis with the FACScan flow cytofluorometer (Becton-Dickinson, Heidelberg, Germany; low power argon laser excitation at 488 nm) as described previously (Chucholowski et al., 1992; Magdolen et al., 1996; Bürgle et al., 1997) . Briefly, human U937 cells -stimulated with phorbol-12-myristate-13-acetate (PMA, 1 mM) for 48 h -were treated with 50 mM glycine-HCl, 0.1 M NaCl, pH 3.0, to dissociate endogenous receptor-bound uPA (1 min, RT). Subsequently, the acidic buffer was neutralised by an appropriate volume of 0.5 M HEPES/ 100 mM NaCl, pH 7.5. The cells were washed, centrifuged and resuspended in PBS/0.1% BSA (adjusted to 10 6 cells/ml). Subsequently, the cells were incubated simultaneously with 16 ng FITC-conjugated pro-uPA and varying amounts of the respective synthetic peptides in question (45 min, RT). Alternatively, cells were pre-incubated with 25 ng FITC-labeled HMW-uPA (15 min), before varying amounts of the respective synthetic peptides or unlabeled HMW-uPA were added. In these displacement studies, the fluorescence mean channel was determined after 1 h incubation at 37 °C.
Fibrin Matrix Degradation Assay
Cell-associated plasminogen activation was assessed using a fibrin degradation test as described previously (Reuning et al., 1995) . Briefly, fibrin gels were prepared in 24-well cell culture plates by incubating 200 µl of 50 mg/ml plasminogen-depleted fibrinogen (Calbiochem, Frankfurt, Germany), 50 µl of 150 mM CaCl 2 , and 50 µl of 60 U/ml thrombin (Novagen, Schwalbach, Germany) for 1 h at 37°C. uPA-producing ovarian cancer OV-MZ-6 cells (Möbus et al., 1992; Fischer et al., 1998) were seeded on top of the fibrin gel (4 × 10 4 cells/well) in the presence of plasminogen (2 µg/ml medium) and varying amounts of the respective synthetic uPA-peptides. As controls, the inhibitory monoclonal antibody against human uPA B-chain, mAb # 394 (10 µg/ml), or the amino-terminal fragment of uPA, ATF (2 µg/ml) (both from American Diagnostica, Pfungstadt, Germany) were used. After 4 h of incubation at 37°C, cell culture supernatants were collected and analysed for the generation of fibrin degradation products (including D-dimer) by ELISA (D-dimer test Gold EIA kit #802, American Diagnostica).
